Subscribe To
MDNA / Medicenna: Multiple Catalysts Ahead In 2023
MDNA News
By InvestorPlace
October 30, 2023
Why Is Medicenna Therapeutics (MDNA) Stock Down Today?
Medicenna Therapeutics (NASDAQ: MDNA ) stock is falling on Monday after the immunotherapy company alerted investors to a delisting notice. Medicenna more_horizontal
By Seeking Alpha
February 28, 2023
Medicenna: Multiple Catalysts Ahead In 2023
Medicenna is testing MDNA11, an IL-2 superkine, with potential in various cancer types, in a phase 1/2 trial called ABILITY. A February 2023 update te more_horizontal
By Seeking Alpha
February 7, 2023
Medicenna Therapeutics Corp. (MDNA) Q3 2023 Earnings Call Transcript
Medicenna Therapeutics Corp. (NASDAQ:MDNA ) Q3 2023 Earnings Conference Call February 7, 2023 8:30 AM ET Company Participants Dan Ferry - Investor Rel more_horizontal
By Seeking Alpha
June 22, 2022
Medicenna Therapeutics Corp. (MDNA) CEO Fahar Merchant on Q4 2022 Results - Earnings Call Transcript
Medicenna Therapeutics Corp. (NASDAQ:MDNA ) Q4 2022 Earnings Conference Call June 22, 2022 8:30 AM ET Company Participants Dan Ferry - IR, LifeSci Adv more_horizontal
By Seeking Alpha
November 12, 2021
Medicenna Therapeutics: Treating Cancer With Immunomodulators
Medicenna Therapeutics has engineered super-versions of interleukins, proteins that mediate communication between cells. Medicenna's candidate for tre more_horizontal
By Seeking Alpha
November 12, 2021
Medicenna Therapeutics: Treating Cancer With Immunomodulators
Medicenna Therapeutics has engineered super-versions of interleukins, proteins that mediate communication between cells. Medicenna's candidate for tre more_horizontal
By Seeking Alpha
November 12, 2021
Medicenna Therapeutics: Treating Cancer With Immunomodulators
Medicenna Therapeutics has engineered super-versions of interleukins, proteins that mediate communication between cells. Medicenna's candidate for tre more_horizontal